NOVARTIS PHARMS CORP

Active trials

• phase3Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Eventsactive not recruitingn=610
• phase3CAR-T Long Term Follow Up (LTFU) Studyrecruitingn=1,105
• phase324 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upactive not recruitingn=100
• phase3Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).recruitingn=550
• phase2Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatmentsrecruitingn=40
• phase2Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- Vrecruitingn=240
• phase3A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathynot yet recruitingn=340
• phase2A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Periodrecruitingn=120